Baughman RP, Niranjan V, Walker G, Burkart C, Paz S, Chong YE, Siefker D, Sun E, Nangle L, Förster S, Muders MH, Farver CF, Lower EE, Shukla S, Culver DA.
Sarcoidosis, Vasculitis and Diffuse Lung Diseases (2023)
Efzofitimod for the Treatment of Pulmonary Sarcoidosis
Culver DA, Aryal S, Barney J, Hsia CCW, James WE, Maier LA, Marts LT, Obi ON, Sporn PHS, Sweiss NJ, Shukla S, Kinnersley N, Walker G, Baughman R. CHEST (2022)
A Novel Neuropilin-2 (NRP2) Antibody for Immunohistochemical Staining of Patient Tissue Samples
European Respiratory Society, 2022
Efzofitimod (ATYR1923) Treatment Reduces Pro-inflammatory Serum Biomarkers in Pulmonary Sarcoidosis Patients
American Thoracic Society, 2022
Safety and Efficacy of Efzofitimod (ATYR1923), a Novel Immunomodulator for Pulmonary Sarcoidosis: Results of a Phase 1b/2a Randomized Placebo-Controlled Trial
American Thoracic Society, 2022
Immunomodulatory Protein ATYR1923 Disrupts an In-Vitro Model of Sarcoid Granuloma Formation
European Respiratory Society, 2021
Treatment with ATYR1923 Reduces Biomarkers in COVID-19 Pneumonia
European Respiratory Society, 2021
Neuropilin-2, the Specific Binding Partner to ATYR1923, Is Expressed in Sarcoid Granulomas and Key Immune Cells
American Thoracic Society, 2020
ATYR1923 Specifically Binds to Neuropilin-2, a Novel Therapeutic Target for the Treatment of Immune-Mediated Diseases
American Thoracic Society, 2020
ATYR1923 Modulates the Inflammatory Response in Experimental Models of Interstitial Lung Disease
American Thoracic Society, 2019